Search Results

Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other pharmaceutical companies to lower drug prices or face consequences.

Join a global community of thought leaders and innovators shaping the future of bioprocessing. Dive into cutting-edge research, share insights with industry experts, and tackle the challenges of bioprocess R&D, scale-up, quality, and analytics.

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures.

LEAP HR: Emerging Biopharma is your only opportunity to uncover how your peers are recognizing and retaining their high-performer R&D employees with no budget, how they’re repositioning career development amongst mass layoffs, and how they are re-imagining culture and employee engagement to keep their scientific workforce motivated.

With 2025 set to be a pivotal year for TA teams, we are excited to announce the return of the 7th LEAP TA: Life Sciences to Boston this September!

BMN 390 fell short of an immunogenicity threshold that BioMarin was looking for to support its further development. Employees working on the program have been redeployed within the company.

The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 people lost their jobs, due largely to Merck cutting roughly 6,000 employees. Sarepta Therapeutics and Moderna also announced significant workforce reductions.

Data Lakes & FAIR Principles: Making Scientific Data Accessible and Actionable

Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and lack of alignment with the FDA regarding an expanded label for Journavx tempered analyst reactions, sending the stock down 13%.